Clinical Trials
Phase 1 Study of bapotulimab in Patients
with Advanced Solid Tumors
This Bayer sponsored study which is active, not recruiting is designed to evaluate the safety and tolerability of bapotulimab , an anti-ILDR2 antibody licensed to Bayer by Compugen, in a dose escalation study as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. An expansion study is active, not recruiting is designed to evaluate the combination of bapotulimab with pembrolizumab in head and neck squamous cell carcinoma.
Bayer resolved to terminate, effective as of February 27, 2023, the parties’ research and development collaboration and license agreement. Bayer will retain the right to continue to provide patients with bapotulimab to the extent required.
Compugen plans to execute its right to receive an exclusive license under Bayer’s intellectual property as required to allow it to continue the development and commercialization of bapotulimab, to the extent it will choose to do so.
Phase 1 Dose Escalation Study of COM902 in Patients with Advanced Malignancies
This study is designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of escalating doses of COM902, an anti-TIGIT antibody, monotherapy in patients with advanced malignancies who have exhausted all available standard therapies.
Phase 1/2 Triple Combination Study of COM701 with Opdivo® (nivolumab) and Anti-TIGIT Antibody BMS-986207 in Patients with Advanced Solid Tumors is active , not recruiting to focus on the triple combination of COM701+COM902+pembrolizumab in metastatic CRC MSS CRC ≤3L and ≤ 3L platinum resistant ovarian cancer
This triple combination study was designed to evaluate the simultaneous blockade of three immune checkpoint pathways, PVRIG (COM701), TIGIT (BMS-986207) and PD-1 (nivolumab), in patients with advanced solid tumors who have exhausted all available standard of care therapies, including those that may be refractory or non-responsive to standard-of-care immune checkpoint inhibitors.
Phase 1 Study of BAY 1905254 in Patients with Advanced Solid Tumors
This Bayer sponsored study is designed to evaluate the safety and tolerability of BAY 1905254, an anti-ILDR2 antibody licensed to Bayer by Compugen, in a dose escalation study as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. An expansion study is designed to evaluate the combination of BAY 1905254 with pembrolizumab in head and neck squamous cell carcinoma.
Compassionate Use Policy
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Adipiscing diam donec adipiscing tristique risus. Massa ultricies mi quis hendrerit dolor magna eget. Sagittis purus sit amet volutpat consequat mauris nunc congue. Volutpat odio facilisis mauris sit amet massa vitae tortor.
